PFD Announces July 31 First-in-Human Implantation of the iKnee
PFD Capital Partners announced the scheduled July 31, 2026, first-in-human implantation of the investigational iKnee at Prime Surgical Center of Newport Beach. The outpatient procedure will be performed by principal investigator Dr. Christopher Woodson, with PFD Director of Clinical Operations Eric Hansen serving as the first patient. The milestone begins the iKnee’s human clinical evaluation […]
PFD Highlights Dr. Daniel Rastein’s Invitation to Participate in FDA Patient-Focused Drug Development Meeting on Nonhealing Chronic Wounds
PFD Capital Partners announced that Dr. Daniel Rastein, Founder and CEO of CassdermaRx, has been invited to participate in the FDA’s upcoming Patient-Focused Drug Development public meeting on nonhealing chronic wounds. The meeting is intended to gather patient and caregiver perspectives on the real-world burden of chronic wounds, current treatment challenges, meaningful outcomes, and clinical […]
PFD Announces Regeneration Biomedical’s FDA Fast Track Designation and Phase IIa Trial Site Selections
PFD Capital Partners announced that Regeneration Biomedical, Inc. received FDA Fast Track designation for RB-ADSC, its investigational autologous adipose-derived stem cell therapy for mild to moderate Alzheimer’s disease, and selected multiple Phase IIa clinical trial sites to support a larger randomized, placebo-controlled evaluation of the treatment. The release explains that RB-ADSC uses Wnt-activated adipose-derived stem […]
PFD Highlights Regeneration Biomedical’s Presentation at ISCT 2026 Annual Meeting
PFD Capital Partners announced that portfolio company Regeneration Biomedical, Inc. presented newly reported clinical findings at the ISCT 2026 Annual Meeting in Dublin, Ireland, highlighting its direct-to-brain regenerative therapy platform for Alzheimer’s disease and other neurodegenerative conditions. The release focuses on completed Phase I findings showing reductions and normalization trends in Alzheimer’s-related biomarkers, including CSF […]
2024 NKC Milestone Progress Update
Announced today by Robert Pryke, PFD Capital Partners LLC, Director and Fund Manager for PFD Management Opportunity Fund 3001 LLC: Significant developments in the HuygensTM Catheter project are under way. Timeline for 2024 is detailed in the attached report from Neuro-Kinesis Corporation (NKC).
Announcing PFD Pro Management Opportunity Fund
Lake Forest, CA – October 19, 2023 – PFD Capital Partners, Inc., Manager of PFDPro Management Fund LLC through its affiliated lender PFD Management LLC successfully closes first position secured exclusive financier provider for a multi-state, multi-modality, nineteen point, Personal Injury Medical Service Provider network.
Third Quarter Development Report on the Huygens/Proteus Technology
Robert Pryke, PFD Capital Partners LLC Director / Fund Manager for PFD Management Opportunity Fund 3001, announced today additional points of interest relating to its portfolio project Neuro-Kinesis Corporation.
Josh Shachar to Speak at Carnap Foundation Event, University of Haifa, Israel
Neuro-Kinesis Corp. (NKC) Founder and CTO, Josh Shachar, a strategic alliance of PFD and portfolio project of the PFD Management Opportunity Fund 3001, LLC, have enjoyed a two-decade long relationship in medical technology development. Josh Shachar will be speaking at the May 28, 2023, Carnap Foundation at the University of Haifa where Neuro-Kinesis Corp. (NKC), […]
End of Year Development Update on NKC’s Huygens™/ Proteus™ Technology
Los Angeles, CA, December 20, 2022 – The following is being provided to share the end-of-year updates on Neuro-Kinesis’ (NKC) progress in forwarding the development of its Huygens™/ Proteus™ Smart Catheter and Robotic Guidance System. The Huygens™/Proteus™ System is NKC’s lead product candidate for its line of SMART Surgical Tool technologies that combine advanced bio-data […]
NKC Release Fourth Quarter Development Report on the Huygens – Proteus™ Robotic Arm Surgical Platform
Neuro-KInesis, Corp. (NKC), is providing the following press release to update its shareholders and strategic partners on the advances made to date in Q422 and to confirm its progress in meeting the milestones set as the company continues to advance the commercialization of its advanced Huygens™ electrophysiology catheter mapping technology and its Proteus™ Robotic-Arm catheter […]